Sao et al. [25] demonstrated that both CDK2 depletion and the pharmacological inhibitor of CDK2 (by SU9516) significantly sensitized three subtypes of AML cells, U937, HL-60, and NB4 cells, to ATRA-induced cell differentiation. The gene discussed is CDK2; the disease is acute myeloid leukemia.